Center of Excellence: Migraine: News & Perspective

• Alert FDA Approves First-in-Class Drug for Migraine Prevention The human monoclonal antibody erenumab has become the first anti-calcitonin-gene-related peptide (CGRP) treatment to receive FDA approval for the prevention of migraine.
  FDA Approvals, May 2018
• New Hope for Migraine Prevention   Dr Arefa Cassoobhoy reports on the effectiveness of a new device in reducing migraine frequency.
  Medscape Internal Medicine, May 2018
• The Future Is Bright for Headache and Migraine Treatments   Dr Lawrence Newman is optimistic that new classes of drugs and treatments, along with newly emerging researchers, will improve treatments for headaches and migraines.
  American Headache Society and Medscape, May 2018
• Ubrogepant Safe, Effective for Migraine in Second Phase 3 Trial Mirroring recently released data from the ACHIEVE-I trial, ACHIEVE-2 trial results also show that oral ubrogepant, a novel CGRP-targeting medication, is safe and effective for treating acute migraine.
  Medscape Medical News, April 2018
• Melatonin for Migraine Headache Prophylaxis Is melatonin effective for reducing the frequency of migraine headaches?
  Medscape Pharmacists, April 2018
• AAN 2018ACHIEVE I: Ubrogepant Meets Endpoints for Acute Migraine Phase 3 trial results show that two doses of oral ubrogepant, a novel CGRP-targeting medication, met the primary endpoints of decreasing acute migraine pain and symptoms compared with placebo.
  Medscape Medical News, April 2018
• AAN 2018Erenumab Prevents Episodic Migraine in Refractory Patients The new phase 3b LIBERTY trial shows erenumab was safe and effective in patients with episodic migraine refractory to at least two previous preventive treatments.
  Medscape Medical News, April 2018
• TMS Device May Offer Nondrug Option for Migraine Prevention An FDA-approved device that delivers transcranial single-pulse magnetic stimulation significantly reduces the number of migraine headache days per month, potentially providing a nondrug prevention option.
  Medscape Medical News, April 2018
• The Facts, Figures, and Faces of Migraine   Headache specialist Dr Lawrence C. Newman discusses how his patients experience migraine and what promising therapies are on the horizon.
  American Headache Society and Medscape, March 2018
• Why Migraine? Why Now? Three leading clinicians discuss why this is an exciting time in migraine care.
  American Headache Society and Medscape, March 2018
• Migraine and Heart Disease: The Link Intensifies   Dr Arefa Cassoobhoy highlights a study that further links migraine and cardiovascular disease.
  Medscape Internal Medicine, March 2018
• Yawning May Herald Migraine Yawning is a unique and reliable symptom in patients with migraine that may offer an opportunity for early treatment, new research suggests.
  Medscape Medical News, February 2018
• Pediatric Migraine Treatments Fail to Outperform Placebo The use of two adult medications in children is now in question. Dr Laurie Barclay discusses what, if anything, we can offer these patients.
  Medscape Neurology, February 2018
• More Evidence Migraine Ups Cardiovascular Disease Risk Previous research shows a strong link between migraine and heart attack and stroke. This study expands the findings to include venous thromboembolism, atrial fibrillation, and other cardiovascular diseases.
  Medscape Medical News, February 2018
• Alert FDA Clears Vagus Nerve Stimulator for Migraine Pain The FDA has expanded the label for the gammaCore vagus nerve stimulator to include treatment of acute pain from migraine in addition to the previously cleared treatment of episodic cluster headache.
  FDA Approvals, January 2018
• Migraine, Essential Tremor Highly Prevalent in NFL Players Retired NFL players are at much greater risk than the general population for multiple neurologic conditions, including chronic migraine, depression, and essential tremor, a new pilot study suggests.
  Medscape Medical News, January 2018
• Can HRT Relieve Migraines in Symptomatic Women?   New research explores the risk/benefit profile of reproductive hormone therapy in menopausal women with migraine.
  Medscape Neurology, January 2018
• Migraine Prevention: Lowest Effective Dose of New Drug Pinpointed Subcutaneous injections of the investigational calcitonin gene-related peptide antibody galcanezumab is especially effective at 120 mg for the prevention of episodic migraine, suggests a phase 2b dosing trial.
  Medscape Medical News, December 2017
• PFO Closure for Migraine: Debates Continue as PREMIUM Published Patient subgroups may benefit, suggest some findings from the sham-controlled trial, at least the third major study of the controversial procedure. Further studies are warranted, says an observer.
  Medscape Medical News, December 2017
• CGRP Antagonists the Next Frontier for Migraine Prevention Monoclonal antibodies that block the CGRP pathway could be the first mechanism-specific preventive treatments for migraine.
  Medscape Medical News, November 2017